Oncology

  • Oncology Research

    Integrated translational bench-to-bedside research is the centerpiece of the cancer program at Cincinnati Children’s Hospital Medical Center. To capitalize on 21st-century innovations in cancer research, we have prioritized alignment of our laboratory research programs with our clinical research enterprise. Our primary objective is to speed the development of new drugs and therapies for children with cancer.  Our research programs focus on key cancer mechanisms and treatment pathways, with close integration of each of our major childhood tumor translational programs. 

    Our priority research areas are:

    1. Cancer and leukemia biology research, with integrated new drug and molecular therapies discovery focused on pediatric malignancies
    2. Personalized cancer therapy approaches using tumor molecular signatures and individualized patient pharmacogenomics
    3. New gene, viral and cellular therapies
    4. Molecular genetics and prevention research to improve outcomes in childhood cancer survivors

    In addition to clinical research involving new cancer and transplant therapies, our biology and specimen procurement protocols have provided important leads to guide our research.  These priorities guide a broad portfolio of investigator-initiated clinical studies here at Cincinnati Children’s, many of which are the direct extension of basic science research carried out at our institution.

    Cincinnati Children’s faculty also developed and lead national clinical trials of novel therapies and transplant approaches.  For more than 50 years, the culture of pediatric oncology has been one of many progressive advances in outcomes through productive national collaborations (e.g., the National Cancer Institute-funded Children’s Oncology Group), and this is a tradition in which we are proud to participate and contribute.

    New Translational Research and Therapies

    Learn more about the innovative research of the Division of Oncology:

    Brain and Spinal Tumors
    Cancer Survivor Center
    Hemangioma and Vascular Malformation
    Kidney Tumors
    Leukemia and Lymphoma
    Liver Tumors
    Musculoskeletal Tumors
    Neuroblastoma
    Neurofibromatosis Tumors
    Retinoblastoma

    The Division of Oncology is part of the Cancer and Blood Diseases Institute. The institute also includes the Divisions of Divisions of Bone Marrow Transplantation and Immune Deficiency, Experimental Hematology and Cancer Biology and Hematology

    The director of the Division of Oncology is John Perentesis, MD, FAAP. Dr. Perentesis is a nationally recognized expert in the development of new therapies for pediatric cancers, leading new clinical trials through the Children’s Oncology Group, the NCI Phase I/Pilot Consortium, and the Department of Defense-funded Neurofibromatosis Consortium.

 
 
  • Leading-Edge Specialized Multidisciplinary Cancer Clinical Programs

    Our cancer programs, including our Advanced Cancer Therapies Center, and the Cancer Survivor Center, are ranked #1 pediatric cancer programs in the nation by U.S. News & World Report. Learn more about our cancer programs.
 
 
  • Oncology

    click to enlarge.

    Oncology

    Row 1: M Absalon, R Nagarajan, B Mizukawa, L Privette-Vinnedge, B Lampkin

    Row 2: A Hammill, M O'Brien, S Wells, R Drissi, B Turpin, J Mangino, M DeWire, J Perentesis, B Weiss

    Row 3: D Adams, L Chow, B Dasgupta, J Geller, T Hummel, C Phillips. S Laupola

  • Division Data Summary

    Research and Training Details
    Faculty21
    Joint Appointment Faculty4
    Research Fellows6
    Support Personnel56
    Direct Annual Grant Support $2,610,576
    Direct Annual Industry Support $108,642
    Peer Reviewed Publications35
    Clinical Activities and Training
    Number of Clinical Staff3
    Number of Clinical Fellows7
    Number of Other Students3
    Inpatient Encounters9,577
    Outpatient Encounters9,430
  • Cancer and Blood Disease Institute

    The Cancer and Blood Diseases Institute aligns strong clinical care and research programs, enhancing collaborations and speeding the transfer of new knowledge from the laboratory to patient care.

    Learn more about the Cancer and Blood Diseases Institute.